Cover image for Drug Approvals Monthly Update: August 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty...

Prime’s Special Investigations Unit is specially trained to protect patients and providers throughout the health care continuum

This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process.

This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process.

Drug Approvals Quarterly Update: July 2024 This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process. Prime...

Jessica Johnson, clinical consultant at Prime Therapeutics, shares some ways to avoid common fraud schemes

Cover image for FDA Decisions Expected_February 2025 Drug pipeline for February 2025 Prime Therapeutics /fda-decisions-expected-february-2025 About Prime Therapeutics Prime Therapeutics logo Prime...

Event features Pat Gleason, AVP, health outcomes at Prime Therapeutics

Cover image for FDA Decisions Expected: November 2024 Drug pipeline for November 2024 Prime Therapeutics /fda-decisions-expected-november-2024 Prime Therapeutics’ FDA Decisions Expected outlines...

References 1. U.S. Food and Drug Administration. Application number 761381: Opdivo Qvantig (nivolumab and hyaluronidase-nvhy). Drugs@FDA. Accessed February 6, 2026....